Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

▤ Summary

Incyte has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront plus potential milestone payments. The deal brings VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease, into Incyte’s hematology portfolio. Incyte expects the acquisition to strengthen its position in bleeding disorders and support future growth in a core therapeutic area. The transaction has board approval and is expected to close in the third quarter of 2026, subject to regulatory review and other customary conditions.

▦ Linked Companies